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Background
The HCV NS5B RNA polymerase is a new target for
drug development for HCV disease. Valopicitabine
(NM283), the prodrug of 2’-C-Methylcytidine (NM107),
has been the most clinically advanced NS5B nucleoside
inhibitor. Nucleoside inhibitors exhibit similar activity
among genotype 1 strains, but their efficacy among
other genotypes is largely unknown. In this study NS5B
amino acid polymorphisms in positions affecting activity
and drug efficacy were investigated in sequences of all
HCV genotypes.
Methods
NS5B amino acid positions significant for catalytic activ-
ity, drug binding and resistance were recovered from
bibliography and molecular modelling. NS5B sequences
were located and downloaded from the HCV sequence
database, and added to experimentally derived NS5B
sequences from drug-naïve patients in order to analyse
significant amino acid positions for natural polymorph-
isms. The most frequent polymorphisms in resistance-
conferring position 282 were further investigated by
docking analysis.
Results
The results revealed a highly conserved active site. Nat-
ural polymorphisms at position 282 were found at low
frequencies, in particular the drug resistant S282T, and
S282R, whose effect is unknown. No genotype-specificity
of polymorphisms could be confirmed.
Discussion
The selection of S282T as a drug-resistant variant when
S282R also exists naturally at the same frequencies
implies that the latter may not confer resistance to
NM283. Molecular modelling suggests that loss of
NM107 activity in the presence of the S282T mutation
may be a result from improper alignment of the drug at
the active site. Overall, the results imply the need for
resistance testing when 2’-C-methyl nucleotide inhibi-
tors are widely available.
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